002252:SZSEShanghai RAAS Blood Products Co., Ltd. Analysis

Technical indicators signal a bearish short‑term outlook: the current price of CNY 5.01 sits below the 20‑day (5.20), 50‑day (5.48) and 200‑day (6.28) moving averages, the RSI is down at 33.8 and the MACD histogram remains negative, suggesting further downside pressure toward the support around CNY 4.72. Valuation appears modestly fair with a trailing P/E of 25 versus an industry average of 24.8, a forward P/E of 13.9 and a price‑to‑book near 1.0, but the stock’s dividend yield of only 0.96% is modest and may be at risk given the balance‑sheet stress.
Fundamentals raise red flags: revenue has contracted by 24.7% YoY, operating cash flow is negative (‑CNY 0.94 bn) and free cash flow is deeply negative (‑CNY 1.66 bn), while debt‑to‑equity is an alarming 12.2×. The company’s ROE of 4% and ROA of 2.3% are low, and the high leverage combined with weak cash generation casts doubt on the sustainability of the dividend despite a low payout ratio.